<?xml version="1.0" encoding="UTF-8" ?><rss version="2.0">
<channel>
<title>Current Research in Cardiovascular Pharmacology - Current Issue</title>
<link>https://scialert.net</link>
<description>Current Research in Cardiovascular Pharmacology</description>
<language>en-us</language>
<copyright>Science Alert</copyright>
<pubDate>Wed, 10 Jun 2026 18:11:57 +0200</pubDate>
<lastBuildDate>Wed, 10 Jun 2026 18:14:14 +0200</lastBuildDate>
<generator>RssPublisher 0.2.0 beta</generator>
<image>
<url>https://scialert.net/images/logo.gif</url>
<title>Current Research in Cardiovascular Pharmacology - Current Issue</title>
<link>https://scialert.net</link>
<height>41</height>
<width>233</width>
<description>Current Research in Cardiovascular Pharmacology</description>
</image>
<item>
Physiological, Biochemical and Molecular Role of Oxidative Stress in Cardiovascular Disease: A Comprehensive Study<title><![CDATA[Physiological, Biochemical and Molecular Role of Oxidative Stress in Cardiovascular Disease: A Comprehensive Study]]></title> 
<description><![CDATA[The metabolic disorder affects about 30% of the US population with escalating prevalence. In this study, the relationships between the metabolic disorder and the occurrence and rigorousness of cardiovascular disease in common and coronary artery disease in particular were explored. The impression of metabolic disorder on outcomes of coronary revascularization therapies and coronary collateral development was specifically compiled. Besides, the association between the metabolic disorder and its individual component pathologies and oxidative stress were also examined. Researchers discuss the apparent lack of encouraging influence of antioxidants on cardiovascular consequences in enormous clinical trials with stress on some of the restrictions of these trials. Lastly, researchers highlight verification for booming application of antioxidant assets of pharmacological agents, including metformin, statins, angiotensin II type I receptor blockers and angiotensin II converting enzyme inhibitors for preclusion and management of the cardiovascular impediments of the metabolic disorder.]]></description>
<link>https://scialert.net/abstract/?doi=crcpaj.2017.1.16</link> 
<pubDate>10 June, 2026</pubDate>
</item>
<item>
Pharmacological Effects of Atorvastatin and Cholesterol and
Blood Pressure<title><![CDATA[Pharmacological Effects of Atorvastatin and Cholesterol and
Blood Pressure]]></title> 
<description><![CDATA[Cholesterol is a precursor for bile acids and steroid hormones. High concentration of cholesterol in the blood leads to
hypercholesterolemia and blood pressure, which may possibly associate with atherosclerotic vascular disease and increased frequency
of vascular events. Decreasing of Low Density Lipoprotein (LDL) cholesterol is an important target for the treatment of cardiovascular
disease (CVD). Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitors are the most effective classes
of drugs for reducing serum LDL cholesterol level. This review focuses on the pharmacological effects of atorvastatin in lowering
cholesterol and control of blood pressure.]]></description>
<link>https://scialert.net/abstract/?doi=crcpaj.2017.17.21</link> 
<pubDate>10 June, 2026</pubDate>
</item>
<item>
Effect of Valsartan on Pharmacokinetics and Pharmacodynamics of Gliclazide in Diabetic rats<title><![CDATA[Effect of Valsartan on Pharmacokinetics and Pharmacodynamics of Gliclazide in Diabetic rats]]></title> 
<description><![CDATA[<b>Background: </b>Diabetes mellitus and hypertension are the most common coexisting complications across the world. For the effective treatment of these types of patients, the treatment regimen should contain antidiabetic agent like gliclazide and antihypertensive agents like valsartan. In view of this combination, in the present study, we have evaluated the effect of valsartan on pharmacokinetics and pharmacodynamics of gliclazide in rats with diabetes. <b>Materials and Methods:</b> Alloxan with a dose of 120 mg kg<SUP>&#150;1</SUP> was used to induce the diabetes in rats, then the rats were treated with test drugs i.e., gliclazide (7.2 mg kg<SUP>&#150;1</SUP>) and valsartan (37 mg kg<SUP>&#150;1</SUP>) at single and multiple doses, by grouping rats as diabetic control, gliclazide alone, gliclazide+valsartan in combination and half therapeutic dose of gliclazide+full dose of valsartan. The blood samples were collected at different intervals and evaluated for pharmacokinetic and pharmacodynamic parameters using blood plasma samples. <b>Results:</b> The pharmacodynamic results from combination of gliclazide+valsartan showed significant difference in blood glucose reduction when compared to gliclazide alone. However, half therapeutic dose of gliclazide+full valsartan dose showed blood glucose reduction as almost equal to gliclazide alone. The pharmacokinetic results showed increased gliclazide plasma concentrations when used in combination with valsartan, when compared to gliclazide+valsaratn with gliclazide alone. Drug interaction was observed between the said drugs. The half dosed gliclazide with valsartan can have significant application for diabetic patients having hypertension, when compared to gliclazide+valsartan. <b>Conclusion: </b> It is showed that combination of gliclazide and valsartan treatment has shown influence on the pharmacokinetics of gliclazide like metabolism/distribution/excretion and shown significant difference in controlling blood glucose. The dosage adjustment of gliclazide is suggestable in patients receiving gliclazide and valsartan.]]></description>
<link>https://scialert.net/abstract/?doi=crcpaj.2017.22.28</link> 
<pubDate>10 June, 2026</pubDate>
</item>
</channel>
</rss>